EP1737858A1 - Sulfonamides - Google Patents

Sulfonamides

Info

Publication number
EP1737858A1
EP1737858A1 EP05716154A EP05716154A EP1737858A1 EP 1737858 A1 EP1737858 A1 EP 1737858A1 EP 05716154 A EP05716154 A EP 05716154A EP 05716154 A EP05716154 A EP 05716154A EP 1737858 A1 EP1737858 A1 EP 1737858A1
Authority
EP
European Patent Office
Prior art keywords
cancer
compounds
diseases
use according
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05716154A
Other languages
German (de)
English (en)
Inventor
Guenter Hoelzemann
Hélène CRASSIER
Alfred Jonczyk
Wolfgang Staehle
Wilfried Rautenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP1737858A1 publication Critical patent/EP1737858A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the object of the invention was to find new compounds with valuable properties, in particular those which can be used for the production of medicaments.
  • the present invention relates to compounds and the use of compounds in which the inhibition, regulation and / or modulation of the signal transduction of kinases, in particular the tyrosine kinases and / or serine threonine kinases plays a role, furthermore pharmaceuticals
  • compositions containing these compounds and the use of the compounds for the treatment of kinase-related diseases are included in the compositions containing these compounds and the use of the compounds for the treatment of kinase-related diseases.
  • the present invention relates to compounds of the formula I which inhibit, regulate and / or modulate the signal transduction of the tyrosine kinases, compositions which contain these compounds and processes for their use for the treatment of p, -.
  • Diseases and conditions related to tyrosine kinase such as angiogenesis, cancer, tumor formation, growth and spread, arteriosclerosis, eye diseases, such as age-related macular degeneration, choroidal neovascularization and diabetic retinopathy, inflammatory diseases, arthritis, thrombosis, fibrosis, neuromelonephritis
  • the tyrosine kinases are a class of enzymes with at least 400 members that are responsible for the transmission of the terminal
  • tyrosine kinases are important factors in cell proliferation, carcinogenesis and cell differentiation.
  • the tyrosine kinases can be divided into receptor tyrosine kinases and cytosolic tyrosine kinases.
  • the receptor tyrosine kinases have an extracellular part, a transmembrane part and an intracellular part, while the cytosolic tyrosine kinases are only present intracellularly (see reviews by Schiessinger and Ullrich, Neuron 9, 383-391 (1992) and 1-20 (1992 )).
  • the receptor tyrosine kinases consist of a large number of transmembrane receptors with different biological effectiveness.
  • a tyrosine kinase subfamily called the HER subfamily consists of EGFR, HER2, HER3 and HER4. Ligands in this receptor subfamily include epithelial growth factor, TGF- ⁇ , amphiregulin, HB-EGF, betacellulin and heregulin.
  • the insulin subfamily which includes INS-R, IGF-IR and IR-R, is another subfamily of these receptor tyrosine kinases.
  • the PDGF subfamily includes the PDGF- ⁇ and - ⁇ - receptor, CSFIR, c- kit and FLK-II.
  • FLK family which consists of the kinase insert domain receptor (KDR), fetal liver kinase-1 (FLK-1), fetal liver kinase-4 (FLK-4) and fms tyrosine kinase-1 (flt-1 ) consists.
  • KDR kinase insert domain receptor
  • FLK-1 fetal liver kinase-1
  • FLK-4 fetal liver kinase-4
  • flt-1 fms tyrosine kinase-1
  • TIE1 is known as a homologue of T1E2.
  • the TIE RTKs are selectively expressed on endothelial cells and are used in processes of angiogenesis and maturation
  • ⁇ c Vascularization can be a valuable target for active ingredients.
  • the cytosolic tyrosine kinases also consist of a large number of subfamilies, including Src, Frk, Btk, Csk, Abi, Zap70, Fes / Fps, Fak,
  • the Src subfamily is one of the largest subfamilies. It includes Src, Yes, Fyn, Lyn, Lck, BIk, Hck, Fgr and Yrk.
  • the Src enzyme subfamily has been linked to oncogenesis. For a more detailed discussion of cytosolic tyrosine kinases, see the work of Bolen Oncogene, 8: 2025-2031
  • Both the receptor tyrosine kinases and the cytosolic tyrosine kinases are involved in cell signaling pathways that lead to various conditions, including cancer, psoriasis and hyper-immune reactions.
  • Various receptor tyrosine kinases and the growth factors that bind them have been suggested to play a role in angiogenesis, although some may promote angiogenesis indirectly (Mustonen and Alitalo, J. Cell Biol. 129: 895-898, 1995).
  • One of these receptor tyrosine kinases is fetal liver kinase 1, also called FLK-1.
  • the human analogue of FLK-1 is the kinase insert domain-containing receptor KDR, which is also known as vascular endothelial cell growth factor receptor 2 or VEGFR-2, because it binds VEGF with high affinity.
  • VEGFR-2 vascular endothelial cell growth factor receptor 2
  • VEGF and KDR represent a ligand-receptor pair that play an essential role in the proliferation of vascular endothelial cells and
  • vasculogenesis Formation and sprouting of the blood vessels, which are called vasculogenesis or angiogenesis, plays.
  • VEGF vascular endothelial growth factor
  • KDR transmembrane tyrosine kinase receptor
  • Flt-1 vascular endothelial cell growth factor receptor 1
  • VEGFR-1 Flt-1
  • VEGRF-2 Flk-1 or KDR
  • VEGFR-3 Flt-
  • VEGFR-2 is of particular interest.
  • Solid tumors can therefore be treated with tyrosine kinase inhibitors, as these tumors are used to support their formation
  • Blood vessels required for growth are dependent on angiogenesis.
  • These solid tumors include monocyte leukemia, brain, urogenital, lymphatic, gastric, larynx, and lung cancer, including lung adenocarcinoma and small cell lung cancer.
  • lung cancer including lung adenocarcinoma and small cell lung cancer.
  • These cancers include pancreatic and breast cancer. Inhibitors of these tyrosine kinases are therefore suitable for the prevention and treatment of proliferative diseases caused by these enzymes.
  • VEGF vascular endothelial growth factor
  • VEGF mRNA and protein levels in the eye are increased due to conditions such as retinal venous occlusion in the primate and reduced p0 2 levels in the mouse, which lead to neovascularization.
  • Intraocularly injected monoclonal anti-VEGF antibodies, or VEGF receptor immunoconjugates inhibit both in primate and in Rodent model the neovascularization in the eye. Regardless of the reason of the reason of the
  • VEGF expression is also greatly increased in hypoxic regions of animal and human tumors in addition to necrosis zones.
  • VEGF is also characterized by the expression of the oncogenes ras, raf, src and p53-
  • Anti-VEGF monoclonal antibodies inhibit the
  • VEGF not as an autocrine mitogenic factor.
  • VEGF therefore contributes to tumor growth in vivo by promoting angiogenesis through its paracrine vascular endothelial cell chemotaxis and mitogenesis activity.
  • monoclonal antibodies also inhibit the growth of typically less vascularized human colon carcinomas in 0 thymus-less mice and reduce the number of tumors arising from inoculated cells.
  • VEGF-binding construct of Flk-1, Flt-1 the mouse KDR receptor homolog shortened to remove the cytoplasmic tyrosine kinase domains, but 5 while maintaining a membrane anchor, virtually stops the growth of a transplantable glioblastoma in the mouse, presumably due to the dominant-negative mechanism of heterodimer formation with trans-Q membranous endothelial cell VEGF receptors.
  • Embryo stem cells which usually grow in the form of solid tumors in the nude mouse, do not form any detectable tumors when all VEGF alleles are knocked out.
  • KDR or Flt-1 are involved in 5 pathological angiogenesis, and these receptors are useful for the treatment of diseases in which angiogenesis is a part overall pathology, e.g. inflammation, diabetic retinal vascularization and various forms of cancer, since it is known that tumor growth is dependent on angiogenesis (Weidner et al., N.
  • Angiopoietin 1 (Ang1), a ligand for the endothelium-specific receptor tyrosine kinase TIE-2, is a new angiogenic factor (Davis et al, Cell, 1996, 87: 1161-1169; Partanen et al, Mol.
  • TIE tyrosine kinase with Ig and EGF homology domains. TIE is used to identify a class of receptor tyrosine kinases that are unique to
  • TIE receptor kinases are typically characterized by the presence of an EGF-like domain and an immunoglobulin (IG) -like domain, which consists of extracellular folding units that are stabilized by disulfide bridges between the chains 0 (Partanen et al Curr. Topics Microbiol. Immunol ., 1999, 237: 159-172).
  • IG immunoglobulin
  • Ang1 and its receptor TIE-2 act during the later stages of vascular development, 5 i.e.
  • TIE-2 would be expected to disrupt the remodeling and maturation of a new vascular system initiated by angiogenesis and thereby the angiogenesis process. Furthermore, inhibition at the kinase domain binding site of 5 VEGFR-2 would block the phosphorylation of tyrosine residues and more serve to interrupt the initiation of angiogenesis. It can therefore be assumed that the inhibition of TIE-2 and / or VEGFR-2 should prevent tumor angiogenesis and serve to slow down or completely eliminate tumor growth. Accordingly, one could treat cancer and others with inappropriate
  • the present invention is directed to methods for regulating, modulating or inhibiting TIE-2 for the prevention and / or treatment of diseases in connection with unregulated or impaired TIE-2 activity.
  • the compounds of the formula I can also be used in the treatment of certain forms of cancer.
  • the compounds of formula I can be used to provide additive or synergistic effects in certain existing cancer chemotherapies and / or can be used to restore the efficacy of certain existing cancer chemotherapies and radiation treatments.
  • the compounds of the formula I can be used to isolate and to study the activity or expression of TlE-2. They are also particularly suitable for use in diagnostic procedures for diseases in connection with unregulated or impaired TIE-2 activity.
  • the present invention further relates to methods for regulating, modulating or inhibiting VEGFR-2 for the prevention and / or treatment of diseases in connection with unregulated or impaired VEGFR-2 activity.
  • the present invention further relates to the compounds of the formula as inhibitors of Raf kinases.
  • Protein phosphorylation is a fundamental process for the regulation of cell functions. The coordinated action of both protein kinases and phosphatases controls the levels of phosphorylation and consequently the activity of specific target proteins.
  • Role of protein phosphorylation is in signal transduction when extracellular signals are amplified and by a cascade of protein
  • Phosphorylation and dephosphorylation events e.g. B. are propagated in the p21 ras / raf way.
  • the p21 ras gene was discovered as an oncogene of the Harvey and Kirsten rat sarcoma viruses (H-Ras and K-Ras, respectively). In humans, characteristic mutations in the cellular Ras gene (c-Ras) were found with many
  • the p21 ras oncogene is an important contributing factor in the development and progression of solid human carcinomas and is mutated in 30% of all human carcinomas (Bolton et al. (1994) Ann. Rep. Med. Chem., 29, 165-74 ; Bos. (1989) Cancer Res., 49, 4682-9).
  • the Ras protein is a key element of the signal transduction cascade, which is controlled by growth factor receptors in almost all tissues (Avruch et al. (1994) Trends Biochem. Sei., 19, 279-83 ).
  • Ras is a guanine nucleotide-binding protein, and the cycling between a GTP-bound activated and a GDP-bound quiescent form is strictly controlled by Ras endogenous GTPase activity and other regulatory proteins.
  • the Ras gene product binds to guanine triphosphate (GTP) and guanine diphosphate (GDP) and 5 hydrolyzes GTP to GDP. Ras is active in the GTP-bound state.
  • the endogenous GTPase activity is reduced in the Ras mutants in cancer cells. weakens, and consequently the protein indicates constitutive growth signals
  • Downstream effectors such as the enzyme Raf kinase.
  • Ras proto oncogene requires a functionally intact C-Raf-1 proto-
  • Oncogene to transduce growth and differentiation signals initiated in higher eukaryotes by receptor and non-receptor tyrosine kinases.
  • Ras Activated Ras is necessary for the activation of the C-Raf-1 proto-oncogene, but the biochemical steps by which Ras activates the Raf-1 protein (Ser / Thr) kinase have now been well characterized. It has been shown to inhibit the effect of active Ras
  • Raf kinase signaling pathway Inhibition of the Raf kinase signaling pathway by administration of deactivating antibodies against Raf kinase or by co-expression of dominant negative Raf kinase or dominant negative MEK (MAPKK), the substrate of Raf kinase, leads to the reversion of transformed cells to the normal growth phenotype, see: Daum et al. (1994) Trends
  • Raf kinase by antisense oligodeoxynucleotides
  • inhibition of Raf kinase in vitro and in vivo has been associated with the inhibition of growth in a number of different human tumor types (Monia et al., Nat. Med. 1996, 2, 668- 75).
  • Raf-serine and threonine-specific protein kinases are cytosolic enzymes that stimulate cell growth in a number of different cell systems (Rapp, U.R., et al. (1988) in The Oncogene Handbook; T.
  • Raf-1 is expressed in all organs and in all cell lines that have been examined, and A and B-Raf are expressed in urogenital and brain tissues, respectively (Storm, S.M. (1990) Oncogene 5: 345-351).
  • Raf genes are proto-oncogenes: they can initiate the malignant transformation of cells if they are expressed in specifically modified forms. Genetic changes that lead to oncogenic activation produce a constitutively active protein kinase by removal or interference with an N-terminal negative regulatory domain of the protein (Heidecker, G., et al. (1990) Mol. Cell. Biol. 10: 2503-2512 ; Rapp, UR, et5 al. (1987) in Oncogenes and Cancer; SA Aaronson, J. Bishop, T. Sugimura, M. Terada, K. Toyoshima and PK Vogt (ed.) Japan Scientific Press, Tokyo).
  • Raf-1 protein serine kinase is a candidate for the "downstream" effector of mitogen signal transduction because Raf oncogenes face growth arrest resulting from blockade of cellular Ras activity due to a cellular mutation (Ras revertant cells) or microinjection of anti-Ras antibodies results (Rapp, UR, et al. (1988) in The Oncogene Handbook, T. Curran, EP Reddy and A. Skalka (ed.), Elsevier Science Publishers; Netherlands, S. 213-253; Smith, MR, et al. (1986) Nature (London) 320: 540-543).
  • the C-Raf function is required for transformation by a number of different membrane-bound oncogenes and for growth stimulation by mitogens contained in sera (Smith, M.R., et al. (1986) Nature (London) 320: 540-543).
  • Raf-1 protein serine kinase activity is regulated by mitogens via phosphorylation (Morrison, DK, et al. (1989) Cell 58: 648-657), which also effects the subcellular distribution (Olah, Z., et al. (1991) Exp. Brain Res. 84: 403; Rapp, UR, et al. (1988) Cold Spring Harbor Sym. Quant. Biol. 53: 173-184.
  • Raf-1 activating growth factors include those from platelets growth factor (PDGF) (Morrison, DK, et al. (1988) Proc. Natl. Acad. Sci. USA 85: 8855-8859), the colony-stimulating factor (Baccarini, M., et al. (1990) EMBO J. 9: 3649-3657), insulin (Blackshear, PJ, et al. (1990) J. Biol. Chem. 265: 12115-12118), epidermal growth factor (EGF) (Morrison, RK, et al. (1988 ) Proc. Natl. Acad. Sci.
  • PDGF platelets growth factor
  • the colony-stimulating factor Baccarini, M., et al. (1990) EMBO J. 9: 3649-3657
  • insulin Blackshear, PJ, et al. (1990) J. Biol. Chem. 265: 12115-12118
  • Raf-1 protein serine kinase translocates into the perinuclear region and the nucleus (Olah, Z., et al. (1991) Exp. Brain Res. 84: 403; Rapp, UR, et al. (1988) Cold Spring Habor Sym. Quant. Biol. 53: 173-184).
  • Cells that contain activated Raf are changed in their gene expression pattern
  • Raf-oncogenes activate transcription from Ap-1 / PEA3-dependent promotors in transient transfeetion assays (Jamal, S., et al. (1990) Science
  • activation includes Raf-1 protein
  • Raf-1 phosphorylation may be a result of a kinase cascade amplified by autophosphorylation, or may be caused entirely by autophosphorylation by binding a putative activation ligand to the Raf-1 regulator.
  • 25 domain is initiated analogously to PKC activation by diacylglycerol (Nishizuka, Y. (1986) Science 233: 305-312).
  • Proteins occur predominantly with serine, threonine or tyrosine residues, and protein kinases were therefore selected according to their specificity for the location of the phosphoryl. H. the serine / threonine kinases and tyrosine kinases 5 classified. Because phosphorylation is such a common process in
  • the compounds according to the invention are inhibitors of the enzyme Raf kinase. Since the enzyme is a "downstream" effector of p21 ras , the inhibitors in pharmaceutical compositions for human or veterinary use prove to be useful when inhibiting the Raf kinase pathway, eg in the treatment of tumors and / or by Raf kinase mediated cancerous cell growth is indicated.
  • the compounds are particularly useful in the treatment of solid carcinomas in humans and animals, e.g. B. of murine cancer, since the
  • the progression of these cancers depends on the Ras protein signal transduction cascade and therefore on the treatment by interrupting the cascade, i. H. by inhibiting the Raf kinase.
  • the compound of the invention or a pharmaceutically acceptable salt thereof is administered for the treatment of 0 diseases mediated by the Raf kinase route, particularly cancer, including solid carcinomas such as carcinomas (e.g. the lungs, the Pancreas, thyroid, bladder or colon), myeloid diseases (e.g. myeloid leukemia) or adenomas (e.g. villous colon adenoma), pathological angiogenesis and metastatic cell migration.
  • the compounds are also useful in the treatment of complement activation dependent chronic inflammation (Niculescu et al.
  • the 5 compounds according to the invention can interact with signaling pathways, in particular with the signaling pathways described herein and preferably the Raf kinase signaling pathway.
  • the compounds according to the invention preferably exhibit an advantageous biological activity which is easily detectable in enzyme-based assays, for example assays as described here.
  • the compounds according to the invention preferably show and bring about an inhibitory effect which is usually documented by IC 50 values in a suitable range, preferably in the micromolar range and more preferably in the nanomolar range 5.
  • these signaling pathways are relevant to various diseases. Accordingly, the compounds of the invention are useful in the prophylaxis and / or treatment of
  • the present invention therefore relates to the invention
  • Compounds according to the invention are therefore inventions as promoters or inhibitors, preferably as inhibitors of the Raf kinase pathway.
  • a preferred subject of the invention is therefore compounds according to the invention as promoters or inhibitors, preferably as inhibitors
  • Raf, - the Raf Kinase are compounds according to the invention as promoters or inhibitors, preferably as inhibitors of one or more Raf kinases, selected from the group consisting of A-Raf, B-Raf and C-Raf-1.
  • a particularly preferred object of the invention are compounds according to the invention as promoters or inhibitors, preferably as inhibitors of C-Raf-1.
  • the present invention furthermore relates to the use of one or more compounds according to the invention in the treatment and / or prophylaxis of diseases, preferably the diseases described here, which are caused, mediated and / or propagated by Raf kinases and in particular diseases which are caused by Raf-0 kinases selected from the group consisting of A-Raf, B-Raf and C-Raf-1 are caused, mediated and / or propagated.
  • the diseases discussed here are usually divided into two groups, hyperproliferative and non-hyperproliferative diseases.
  • psoriasis, arthritis, inflammation, endometriosis, 5 scarring, benign prostatic hyperpiasia, immunological diseases, autoimmune diseases and immunodeficiency diseases are considered not to be cancerous diseases, of which arthritis, inflammation, immunological diseases, autoimmune diseases and immunodeficiency diseases are usually considered non-hyperproliferative
  • brain cancer lung cancer, squamous cell cancer, bladder cancer, stomach cancer,
  • Pancreatic cancer liver cancer, kidney cancer, colorectal cancer, breast cancer, head cancer, neck cancer, esophageal cancer, gynecological cancer, thyroid cancer, lymphoma, chronic leukemia and acute leukemia
  • cancerous diseases to consider all of which are commonly considered hyperproliferative diseases.
  • cancerous cell growth and in particular cancerous cell growth mediated by Raf kinase, is a disease that is a goal of the present
  • the present invention therefore relates to compounds according to the invention as medicaments and / or active pharmaceutical ingredients in the treatment and / or prophylaxis of the diseases mentioned and the use of compounds according to the invention for the preparation of a pharmaceutical for the treatment and / or prophylaxis of the diseases mentioned and also a process for Treatment of said diseases comprising the administration of one or more compounds according to the invention to a patient in need of such an administration. 5
  • the compounds according to the invention have an in vivo antiproliferative effect in a xenograft tumor model.
  • the compounds of the invention are administered to Q a patient with a hyperproliferative disease, e.g. For example, to inhibit tumor growth, to reduce inflammation associated with lymphoproliferative disease, to inhibit graft rejection or neurological damage due to tissue repair, etc.
  • a hyperproliferative disease e.g. For example, to inhibit tumor growth, to reduce inflammation associated with lymphoproliferative disease, to inhibit graft rejection or neurological damage due to tissue repair, etc.
  • the present compounds are useful for prophylactic or therapeutic purposes.
  • the term "treat" is used to refer to both the Disease prevention as well as pre-existing treatment
  • the host or patient can belong to any mammalian species, e.g. B. a primate species, especially humans; Rodents, including mice, rats and hamsters; Rabbits; Horses, cattle, dogs, cats, etc. Animal models are of interest for experimental studies, providing a model for treating a human disease.
  • mammalian species e.g. B. a primate species, especially humans; Rodents, including mice, rats and hamsters; Rabbits; Horses, cattle, dogs, cats, etc. Animal models are of interest for experimental studies, providing a model for treating a human disease.
  • the susceptibility of a particular cell to treatment with the compounds according to the invention can be determined by testing in vitro. Typically, a culture of the cell is combined with a compound of the invention at various concentrations for a period of time sufficient to enable the active agents to induce cell death or to inhibit migration, usually between about an hour and a week. Cultured cells from a biopsy sample can be used for in vitro testing. The viable cells remaining after treatment are then counted.
  • the dose varies depending on the specific compound used, the specific disease, the patient status, etc. Typically, a therapeutic dose is sufficient to avoid the undesirable
  • Viability of the patient is maintained.
  • the treatment will generally continue until there is a substantial reduction, e.g. B. at least about 50% reduction in cell load and can be continued until essentially no more unwanted cells are detected in the body.
  • Suitable models or model systems have been developed by various scientists to identify a signal transmission path and to demonstrate interactions between different signal transmission paths, e.g. Cell culture models (e.g. Khwaja et al.,
  • EMBO, 1997, 16, 2783-93 models of transgenic animals (e.g. White et al., Oncogene, 2001, 20, 7064-7072).
  • interacting compounds can be used to modulate the signal (e.g. Stephens et al., Biochemical J., 2000, 351, 95-105).
  • the compounds according to the invention can also be used as reagents for testing kinase-dependent signal transmission paths in animals and / or cell culture models or in the clinical diseases mentioned in this application.
  • Measuring kinase activity is a technique well known to those skilled in the art.
  • Generic test systems for determining kinase activity with substrates e.g. Histone (e.g. Alessi et al., FEBS Lett. 1996, 399, 3, pages 333-338) or the basic myelin protein are described in the literature (e.g. Campos-Gonzalez, R. and Glenney, Jr., JR 1992, J. Biol. Chem. 267, page 14535).
  • phospho-AK specific phospho-antibodies
  • the phospho-AK only binds the phosphorylated substrate. This binding can be detected with a second peroxidase-conjugated anti-sheep antibody by chemiluminescence (Ross et al., 2002, Biochem. J., immediately before publication, manuscript BJ20020786).
  • the sufferings of interest include, but are not limited to, the following sufferings.
  • the compounds of the invention are useful in the treatment of a number of different conditions in which proliferation and / or migration of smooth muscle cells and / or inflammatory cells is present in the intimal layer of a vessel, resulting in reduced blood flow to this vessel, e.g. B. in neointimal occlusive lesions.
  • Occlusive graft vascular diseases of interest include atherosclerosis, coronary vascular disease after transplantation, venous graft stenosis, peri-anastomotic prosthetic restenosis, restenosis after angioplasty or stent placement and the like.
  • the compounds according to the invention are also suitable as p38 kinase inhibitors.
  • the invention relates to compounds of the formula
  • R 4 , R 5 each independently of one another are H, A, OH, OA, alkenyl having 2 to 6 C atoms, alkynyl having 2 to 6 C atoms, N0 2 , NH 2 ,
  • NHA NHA, NA 2 , shark, CN, COOH, COOA,
  • R 6 , R 7 each independently of one another H, A, Hai, OH, OA or CN, R 8 , R 9 each independently of one another H or A,
  • Het 1 is a mono- or dinuclear saturated, unsaturated or aromatic heterocycle with 1 to 4 N-, O- and / or S-
  • Atoms which are unsubstituted or once, twice or three times by shark A, OA, OH, alkenyl with 2 to 6 C atoms, alkynyl with 2 to 6 C atoms, N0 2 , NH 2 , NHA, NA 2 , COOH, COOA,
  • Hai F, Cl, Br or I, n are 0, 1, 2 or 3 0, and their pharmaceutically usable derivatives, solvates, salts,
  • the invention also relates to the optically active forms
  • Solvates are e.g. Mono- or dihydrates or
  • Formula I also includes the tautomeric compounds of the formulas Ia and Ib
  • compositions are e.g. the salts of the compounds according to the invention and also so-called prodrug compounds.
  • Prodrug derivatives are understood with z. B. alkyl or acyl groups, sugars or oligopeptides modified compounds of formula I, which are quickly cleaved in the organism to the active compounds of the invention.
  • the term "effective amount” means the amount of a drug or active pharmaceutical ingredient that elicits a biological or medical response in a tissue, system, animal or human, e.g. is sought or sought by a researcher or medical professional.
  • terapéuticaally effective amount means an amount which, compared to a subject who has not received this amount, does the following: improved healing, healing, prevention or elimination of a
  • terapéuticaally effective amount also includes
  • the invention also relates to the use of mixtures of the compounds of the formula I, e.g. Mixtures of two diastereomers e.g. in a ratio of 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1: 10, 1: 100 or 1: 1000.
  • the invention relates to the compounds of formula I and their salts and a process for the preparation of compounds of formula I 0 according to claims 1-10 and their pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers, characterized in that a compound of formula II
  • R 6 , R 7 , R 8 and R 9 have the meanings given in claim 1, 5 with a compound of formula III X-S0 2 CI III
  • A is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore 0 also pentyl, 1-, 2- or 3-methylbutyl, 1, 1-, 1, 2- or 2,2-dimethylpropyl, 1-ethyl propyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1, 1-, 1, 2-, 1, 3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1, 1, 2- or 1, 2,2-trimethylpropyl, further5 preferred eg Trifluoromethyl.
  • alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl , Pentafluoroethyl or Q 1, 1, 1-trifluoroethyl.
  • A also means cycloalkyl.
  • Cycloalkyl preferably means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • Alkylene is preferably unbranched and is preferably methylene, 5 ethylene, propylene, butylene or pentiene.
  • R 1 , R 2 , R 3 , R 4 , R 5 each independently, preferably, for example, H; A, such as methyl or ethyl; OH, OA, such as methoxy, ethoxy, propoxy or trifluoromethoxy; Shark or CN.
  • R 6 and R 7 are preferably H.
  • R 8 and R 9 are preferably H.
  • Het 1 preferably denotes a mononuclear or dinuclear saturated, 10 unsaturated or aromatic heterocycle having 1 to 4 N, O and / or S atoms, which is unsubstituted or can simply be substituted by COOA.
  • Het 1 means, for example, 2- or 3-furyl, 2- ⁇ ⁇ or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazoIyi, 1-, 3rd -, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazoIyl, 2 -, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, further preferably 1, 2,3-triazoM-, -4- or -5-yl, 1, 2,4-triazoI- 1-, -3- or 5-yi, 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4- or -5-yl, 0 1, 2,4-oxadiazol-3- or -5-yl , 1, 3,4-thiadiazol-2- or -5-yl, 1, 2,4-thiadiazol
  • heterocytic radicals can also be partially or completely hydrogenated.
  • Het 1 can, for. B. also mean 2,3-dihydro-2-, -3-, -4- or -5-furyl,
  • Het 1 very particularly preferably denotes pyridyl, 2,3- or 3,4-ethylenedioxyphenyl.
  • Het means e.g. 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2 -, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or
  • 5-thiazoIyl 3-, 4- or 5-isothiazolyI, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-
  • Pyrimidinyl further preferably 1, 2,3-triazoM-, -4- or -5-yl, 1, 2,4- Triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4- or -5-yl,
  • Isoindolyl 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-
  • Benzisothiazolyl 4-, 5-, 6- or 7-benz-2,1, 3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3- , 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyI, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyI, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo [1, 4] oxazinyl, more preferably 1, 3-benzodioxol-5 -yl, 1, 4-benzodioxan-6-yl, 2,1, 3-benzothiadiazol-4- or -5-yl or 2,1, 3-benzoxadiazol-5-yl.
  • the heterocytic radicals can also be partially or completely hydrogenated.
  • Het can, for. B. also mean 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2 - or -3-furyl, 1, 3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2 - or -4-imidazolyi, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyI, tetrahydro-1-, -3- or -4-pyrazolyl, 1, 4
  • Het means a mononuclear, saturated heterocycle having 1 to 3 N, O and / or S atoms, which is unsubstituted or can simply be substituted by COOA.
  • the mononuclear saturated heterocycle here means particularly preferably piperidinyl, pyrrolidinyl, morpholinyl or piperazinyl.
  • Het very particularly preferably denotes 1-, 2-, 3- or 4-piperidinyl or 2-, 3- or 4-morpholinyl, it being possible for Het to be substituted by COOA.
  • ⁇ C shark is preferably F, Cl or Br, but also I, particularly preferably F or Cl.
  • Alkenyl has 2, 3, 4, 5 or 6 carbon atoms and is preferably vinyl, 1- or 2-propenyl, 1-butenyl, isobutenyl, sec-butenyl, further preferred is 0 1-pentenyl, isopentyl or 1-hexenyl.
  • Alkynyl has 2, 3, 4, 5 or 6 carbon atoms and is preferably ethynyl, propin-1-yl, furthermore butyn-1, butyn-2-yl, pentyn-1, pentyn-2 or pentyne - 5 3-yl.
  • the compounds of formula I can have one or more chiral centers and therefore exist in various stereoisomeric forms.
  • Formula I encompasses all of these forms. 5 Accordingly, the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above.
  • Some preferred groups of compounds can be expressed by the following sub-formulas Ia to Ih, which correspond to the formula I and in which the radicals not specified have the meaning given for the formula I, but in which
  • R 5 4, Q R5 each independently represent H, A, OH, OA, Hai or CN;
  • Ic Het denotes a mononuclear saturated heterocycle having 1 to 3 N, O and / or S atoms, which is unsubstituted or can simply be substituted by COOA;
  • Het 1 is a mono- or dinuclear saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and / or S atoms, which is unsubstituted or can be simply substituted by COOA;
  • R 4 , R 5 each independently or CN
  • Het 1 is a mono- or dinuclear saturated, unsaturated or aromatic heterocycle with 1 to 4 N, O and / or S atoms, which is unsubstituted or can be simply substituted by COOA, alkyl having 1 to 10 C atoms, where 1-7 H atoms can also be replaced by F and / or chlorine,
  • the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.
  • the reaction is usually carried out in an inert solvent, in the presence of an organic base such as triethylamine, dimethylaniline,
  • the reaction time is between a few minutes and 14 days
  • the reaction temperature is between about 0 ° and 150 °, normally between 15 ° and 90 °, particularly preferably between 15 and 30 ° C.
  • Suitable inert solvents are e.g. Hydrocarbons like hexane,
  • dichloromethane Dichloromethane
  • Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol
  • Ethers such as diethyl ether, diisopropyl ether, Tetrahydrofuran (THF) or dioxane
  • Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone;
  • Amides such as acetamide, dimethylacetamide or dimethylformamide (DMF);
  • Nitriles such as acetonitrile; Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulphide; Carboxylic acids such as formic acid or acetic acid; Nitro compounds such as nitromethane or nitrobenzene; Estef such as ethyl acetate or mixtures of the solvents mentioned.
  • Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulphide
  • Carboxylic acids such as formic acid or acetic acid
  • Nitro compounds such as nitromethane or nitrobenzene
  • Estef such as ethyl acetate or mixtures of the solvents mentioned.
  • the compounds according to the invention mentioned can be used in their final non-salt form.
  • the present invention also encompasses the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by methods known in the art.
  • Most of the pharmaceutically acceptable dosage forms of the compounds of the formula I are prepared conventionally. If the compound of the formula I contains a carboxylic acid group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base addition salt.
  • Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; Alkaline earth metal hydroxides such as barium hydroxide and calcium hydroxide; Alkali metal alcoholates, for example potassium ethanolate and sodium propanolate; as well as various organic bases such as piperidine, diethanolamine and N-methylglutamine.
  • alkali metal hydroxides including potassium hydroxide, sodium hydroxide and lithium hydroxide
  • Alkaline earth metal hydroxides such as barium hydroxide and calcium hydroxide
  • Alkali metal alcoholates for example potassium ethanolate and sodium propanolate
  • various organic bases such as piperidine, diethanolamine and N-methylglutamine.
  • the aluminum salts of the compounds of formula I also count.
  • acid addition salts can be formed by reacting these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and their corresponding salts such as sulfate, nitrate or phosphate and the like as well as alkyl and monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate, as well as other organic acids and their corresponding salts such as acetate, trifluoroacetate, tartrate, maleate, succinate,
  • organic and inorganic acids for example hydrogen halides such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and their corresponding salts such as sulfate, nitrate or phosphate and the like as well as alkyl and monoarylsulfonates such as ethanesulfonate, toluenesulfonate
  • compositions of the formula I include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphor sulfonate, caprylate, chloride, chlorine , citrate, cyclopentanepropionate, digluconate, phosphate dihydrogen, dinitrobenzoate, dodecylsulfate, ethanesulfonate, fumarate, galacterate (from Schieimklare), galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydroch
  • the base salts of the compounds according to the invention also include aluminum, ammonium, calcium, copper, iron (III), iron (II), lithium, magnesium, manganese (III), manganese (II), potassium -, sodium and zinc salts, but this should not be a limitation.
  • Preferred among the salts mentioned above are ammonium; the alkali metal salts sodium and potassium; and the alkaline earth metal salts calcium and magnesium.
  • Salts of the compounds of the formula I which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example arginine, betaine , Caffeine, chloroprocaine, choline, N, N'-dibenzylethylenediamine (Benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-
  • Hydrabamine isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procain, purines,
  • Compounds of the present invention which contain basic nitrogen-containing groups can be prepared using agents such as (C 1 -C 4 ) alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; Di (-C-C) alkyl sulfates, such as dimethyl, diethyl and diamyl sulfate; (C 1 0- Ci 8 ) alkyl halides, for example decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; as well as aryl (C 1 -C 4 ) alkyl halides, for example benzyl chloride and phenethyl bromide, quartemize.
  • Such salts can be used to prepare both water-soluble and oil-soluble compounds according to the invention.
  • the above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, Sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, but this is not intended to be a limitation.
  • the acid addition salts of basic compounds of the formula I are prepared by contacting the free base form with a sufficient amount of the desired acid, so that the salt is prepared in the usual way.
  • the free base can be regenerated in a conventional manner by contacting the salt form with a base and isolating the free base.
  • the free base forms differ in certain sem sense of their corresponding salt forms in relation to certain physical properties such as solubility in polar solvents; in the
  • the pharmaceutically acceptable base addition salts of the compounds of the formula I are formed with metals or amines such as alkali metals and alkaline earth metals or organic amines.
  • metals are sodium, potassium, magnesium and calcium.
  • Preferred organic amines are N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.
  • the base addition salts of acidic compounds according to the invention are prepared by contacting the free acid form with a sufficient amount of the desired base, whereby the salt is prepared in the usual way.
  • the free acid can be regenerated in a conventional manner by contacting the salt form with an acid and isolating the free acid.
  • the free acid forms differ in a sense from their corresponding salt forms in terms of certain physical properties such as solubility in polar solvents; in the context of the invention, however, the salts otherwise correspond to their respective free acid forms.
  • a compound according to the invention contains more than one group which can form such pharmaceutically acceptable salts, the invention also includes multiple salts.
  • Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium and trihydrochloride, but this is not intended to be a limitation.
  • the term "pharmaceutically acceptable salt” in the present context an active ingredient is to be understood which contains a compound of the formula I in the form of one of its salts, in particular when this salt form of the active ingredient has improved pharmacokinetic properties compared to the free form of the active ingredient or any other salt form of the active ingredient which has been used previously Gives properties.
  • the pharmaceutically acceptable salt form of the active ingredient can also give this active ingredient a desired pharmacokinetic property which it did not previously have, and can even have a positive influence on the pharmacodynamics of this active ingredient with regard to its therapeutic effectiveness in the body.
  • the invention also relates to the intermediate compounds of the formula 1-1
  • R 6 , R 7 each independently of one another H, A, shark, OH, OA or CN, R 8 , R 9 each independently of one another H or A,
  • R 10 NH 2 or N0 2 A each independently of one another alkyl having 1 to 10 C atoms, where 1-7 H atoms can also be replaced by F and / or chlorine, sharks mean F, Cl, Br or I, and their solvates, salts, tautomers and stereoisomers, including their mixtures in all proportions.
  • Some preferred groups of compounds of formula 1-1 can be expressed by the following sub-formulas 1-1 a to 1-1 b, which is the
  • the invention further relates to medicaments containing at least one compound of the formula I and / or its pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios, and, if appropriate, carriers and / or auxiliaries.
  • compositions can be presented in the form of dose units containing a predetermined amount of active ingredient per dose unit.
  • a unit can contain, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the condition of the disease treated, the route of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be presented in the form of dose units containing a predetermined amount of active ingredient per dose unit.
  • Preferred dosage unit formulations are those which contain a daily dose or partial dose, as stated above, or a corresponding fraction thereof of an active ingredient.
  • such pharmaceutical formulations can be produced using one of the methods generally known in the pharmaceutical field.
  • Pharmaceutical formulations can be administered by any suitable route, for example orally
  • Such formulations can be prepared by any method known in the pharmaceutical art, for example by the
  • Active ingredient is brought together with the carrier (s) or auxiliary (s).
  • compositions adapted for oral administration can be used as separate units, e.g. Capsules or tablets; Powder or granules; Solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam dishes; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
  • the active ingredient component in the case of oral administration in the form of a tablet or capsule, can be treated with an oral, non-toxic and pharmaceutically acceptable inert carrier, such as e.g. Ethanol, glycerin, water etc. combine.
  • an oral, non-toxic and pharmaceutically acceptable inert carrier such as e.g. Ethanol, glycerin, water etc. combine.
  • Powders are made by comminuting the compound to an appropriate fine size and with a similarly comminuted pharmaceutical carrier such as e.g. an edible carbohydrate such as
  • Starch or mannitol is mixed.
  • a flavor, preservative, dispersant and color may also be present.
  • Capsules are made by making a powder mixture as described above and filling shaped gelatin shells with it.
  • Lubricants and lubricants such as highly disperse silica, talc, Magnesium stearate, calcium stearate or polyethylene glycol in solid form can be added to the powder mixture before the filling process.
  • Disintegrants or solubilizers e.g. Agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medication after taking the capsule.
  • suitable binding agents can also be incorporated into the mixture.
  • suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, sweeteners from corn, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, etc.
  • Lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and others.
  • the disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and others.
  • the tablets are formulated by, for example, producing, granulating or mixing a powder mixture is pressed dry, a lubricant and a disintegrant are added and the whole is pressed into tablets.
  • a powder mixture is produced by the compound, which has been comminuted in a suitable manner, with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethyl cellulose, an alginate, gelatin or polyvinylpyrrolidone, a solution-reducing agent, such as, for example, paraffin Absorption accelerator, such as a quaternary salt and / or an absorbent, such as bentonite, kaolin or dicalcium phosphate, is mixed.
  • a binder such as, for example, carboxymethyl cellulose, an alginate, gelatin or polyvinylpyrrolidone
  • a solution-reducing agent such as, for example, paraffin Absorption accelerator, such as a quaternary salt and /
  • the powder mixture can be granulated by wetting it with a binder, such as syrup, starch paste, Acadia-Schieim or solutions made of cellulose or polymer materials, and pressing it through a sieve.
  • a binder such as syrup, starch paste, Acadia-Schieim or solutions made of cellulose or polymer materials
  • the powder mixture can be run through a tableting machine, with irregularly shaped lumps which form in Granules are broken up.
  • the granules can be greased by adding stearic acid, a stearate salt, talc or mineral oil to prevent sticking to the tablet molds. The greased mixture is then compressed into tablets.
  • the compounds according to the invention can also be used with a free-flowing inert
  • a transparent or opaque protective layer consisting of a shellac seal, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.
  • Oral liquids e.g. Solution, syrups and elixirs can be prepared in unit dosage forms so that a given quantity contains a given amount of the compound.
  • Syrups can be made by dissolving the compound in an aqueous solution with a suitable taste, while elixirs are made using a non-toxic alcoholic vehicle.
  • Suspensions can be formulated by dispersing the compound in a non-toxic vehicle.
  • Solubilizers and emulsifiers e.g. ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavor additives such as e.g. Peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, etc. can also be added.
  • Dosage unit formulations for oral administration can optionally be enclosed in microcapsules.
  • the formulation can also be prepared in such a way that the release is prolonged or delayed, for example by coating or embedding particulate material in polymers, wax and the like.
  • the compounds of the formula I and salts, solvates and physiologically functional derivatives thereof can also be administered in the form of liposome delivery systems, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. 5
  • Liposomes can be made from various phospholipids, e.g.
  • Cholesterol, stearylamine or phosphatidylcholines Cholesterol, stearylamine or phosphatidylcholines.
  • Functional derivatives thereof can also be supplied using monoclonal antibodies as individual carriers to which the connecting molecules are coupled.
  • the compounds can also be coupled with soluble polymers as targeted drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl methacrylamide phenol, polyhydroxyethylaspartamide phenol or polyethylene oxide polylysine, substituted with palmitoyl residues.
  • the compounds can be attached to a class of biodegradable polymers which are suitable for achieving a controlled release of a pharmaceutical, for example polylactic acid, polyepsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates and crosslinked or amphipatic block copolymers of hydrogels. 5
  • compositions adapted for transdermal administration can be administered as independent patches for prolonged, close contact with the epidermis of the recipient.
  • the active ingredient can be supplied from the patch by means of iontophoresis, as generally described in Pharmaceutical Research, 3 (6), 318 (1986).
  • compositions 5 adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • the formulations are preferably applied as a topical ointment or cream.
  • the active ingredient can be used either with a paraffinic or with a water-miscible cream base.
  • the active ingredient can be formulated into a cream with an oil-in-water cream base or a water-in-oil base.
  • eye drops wherein the active ingredient in a suitable carrier, especially an aqueous solvent, is dissolved or suspended c.
  • compositions adapted for topical application in the mouth include lozenges, lozenges and mouthwashes.
  • compositions adapted for rectal administration can be administered in the form of suppositories or enemas.
  • compositions adapted for nasal administration in which the carrier substance is a solid, contain a coarse powder with a particle size, for example in the range of 20-500 micrometers, which is administered in the manner in which snuff is taken up, ie by rapid inhalation via the nasal passages Q from a container with the powder held close to the nose.
  • Suitable formulations for administration as a nasal spray or nasal drops with a liquid as carrier include active ingredient solutions in water or oil. 5
  • Formulations include fine particulate dusts or mists using various types of pressurized dispensers
  • Aerosols, nebulizers or insufflators can be generated.
  • compositions adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
  • compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions, the antioxidants, buffers, bacteriostatics and solutes, through which the formulation is isotonic with the blood of the person to be treated
  • Recipient is made included; as well as aqueous and non-aqueous sterile suspensions, which can contain suspending agents and thickeners.
  • the formulations can be in single dose or multiple dose containers, e.g. sealed ampoules and vials, presented and stored in the freeze-dried (lyophilized) state so that only the addition of the sterile carrier liquid, e.g. Water for injections is required immediately before use.
  • sterile carrier liquid e.g. Water for injections
  • Injection solutions and suspensions prepared according to the recipe can be made from sterile powders, granules and tablets.
  • formulations may contain, in addition to the above-mentioned ingredients, other means common in the art with respect to the particular type of formulation; for example, formulations suitable for oral administration may contain flavorings.
  • a therapeutically effective amount of a compound of formula I depends on a number of factors including, for example, age and Weight of the animal, the exact disease state that requires treatment, its severity, the nature of the formulation and the route of administration, and is ultimately determined by the treating doctor or veterinarian. However, an effective amount is one
  • Growth e.g. Colon or breast carcinoma, generally in the range of 0.1 to 100 mg / kg body weight of the recipient (mammal) per day and particularly typically in the range of 1 to 10 mg / kg body weight per
  • the actual amount per day would usually be between 70 and 700 mg, which amount as a single dose per day or more usually in a series of divided doses (such as two, three, four, five or six) per Given day
  • a r can be so that the total daily dose is the same.
  • An effective amount of a salt or solvate or a physiologically functional derivative thereof can be determined perse as a proportion of the effective amount of the compound of the invention. It can be assumed that similar dosages are suitable for the treatment of the other disease states mentioned above.
  • the invention further relates to medicaments comprising at least one compound of the formula I and / or its pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios, and at least one further active pharmaceutical ingredient.
  • the invention also relates to a set (kit) consisting of separate Q packs of
  • the set contains suitable containers, such as boxes or cartons, individual bottles, bags or ampoules.
  • the set can contain, for example, separate ampoules, in each of which an effective amount of a compound of the formula I and / or its pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios, and an effective amount of a further active pharmaceutical ingredient are dissolved or lyophilized Form is present.
  • the present compounds are suitable as pharmaceutical active substances for mammals, in particular for humans, in the treatment of tyrosine kinase-related diseases.
  • diseases include tumor cell proliferation, pathological neovascularization (or angiogenesis) that promotes the growth of solid tumors, neovascularization (diabetic retinopathy, age-related macular degeneration and the like) and inflammation (psoriasis, rheumatoid arthritis and the like).
  • the present invention includes the use of the compounds of formula I and / or their physiologically acceptable salts and solvates for the manufacture of a medicament for the treatment or prevention of cancer.
  • Preferred carcinomas for the treatment come from the group of brain carcinoma, urogenital tract carcinoma, carcinoma of the lymphatic system, gastric carcinoma, larynx carcinoma and lung carcinoma.
  • Another group of preferred forms of cancer are monocyte leukemia, lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma and breast carcinoma.
  • the use of the compounds according to the invention and / or their physiologically acceptable salts and solvates for the manufacture of a medicament is also included Treatment or prevention of an illness involving angiogenesis.
  • Such a disease, in which angiogenesis is involved, is one
  • Eye disease such as retinal vascularization, diabetic retinopathy, 5 age-related macular degeneration and the like.
  • Such inflammatory diseases include, for example, rheumatoid arthritis, psoriasis, contact dermatitis, late-type hypersensitivity reaction and the like.
  • ⁇ K Also included is the use of the compounds of the formula I and / or their physiologically acceptable salts and solvates for the manufacture of a medicament for the treatment or prevention of a tyrosine kinase-related illness or a tyrosine kinase-related illness in a mammal, whereby this method is used to treat a sick mammal, that requires such treatment, administered a therapeutically effective amount of a compound of the invention.
  • the therapeutic amount depends on the respective disease and can be determined by the person skilled in the art without any great effort.
  • the present invention also includes the use of compounds of formula I and / or their physiologically acceptable salts and solvates for the manufacture of a medicament for the treatment or prevention of retinal vascularization.
  • tyrosine kinase-related diseases or conditions refers to pathological conditions that result from the activity of one or more 5
  • Tyrosine kinases are dependent.
  • the tyrosine kinases are either directly or indirectly involved in the signal transduction pathways of various cell activities, including proliferation, adhesion and migration as well as differentiation.
  • Diseases associated with tyrosine kinase activity are dependent.
  • the tyrosine kinases are either directly or indirectly involved in the signal transduction pathways of various cell activities, including proliferation, adhesion and migration as well as differentiation.
  • tumor cell proliferation pathological neovascularization that promotes the growth of solid tumors
  • pathological neovascularization that promotes the growth of solid tumors
  • neovascularization in the eye diabetic retinopathy, age-related macular degeneration and the like
  • inflammation psoriasis, rheumatoid arthritis
  • the compounds of formula I can be administered to patients for the treatment of cancer.
  • the present compounds inhibit tumor angiogenesis and thus influence the growth of tumors (J. 0 Rak et al. Cancer Research, 55: 4575-4580, 1995).
  • the angiogenesis-inhibiting properties of the present compounds of formula I are also suitable for the treatment of certain forms of blindness which are associated with retinal vascularization.
  • the compounds of the formula I are also suitable for the treatment of certain bone pathologies such as osteosarcoma, osteoarthritis and rickets, which is also known under the name oncogenic osteomalacia (Hasegawa et al., Skeletal Radio !. 28, pp.
  • VEGF vascular endothelial growth factor
  • VEGF directly promotes osteoclastic bone resorption through the KDR / Flk-1 expressed in mature osteoclasts
  • the present compounds are also suitable for treatment and prevention of conditions associated with 5 bone resorption, such as osteoporosis and Paget's disease.
  • the compounds can be characterized by the fact that they have cerebral edema
  • the invention thus relates to the use of compounds 10 of the formula I, and their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all proportions, for the manufacture of a medicament for the treatment of diseases in which the inhibition, regulation and / or modulation A ⁇ the signal transduction of kinases plays a role.
  • Kinases are preferably selected from the group of tyrosine kinases and Raf kinases. 0
  • the tyrosine kinases are preferably TIE-2, VEGFR, PDGFR, FGFR and / or FLT / KDR.
  • Compounds according to claim 1 are influenced.
  • the use for the treatment of a disease is particularly preferred, the disease being a solid tumor.
  • the solid tumor is preferably selected from the group of tumors of the squamous epithelium, the blisters, the stomach, the kidneys, the head and neck, the esophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the Urogenital tract, lymphatic system, stomach, larynx and / or lungs.
  • the solid tumor is also preferably selected from the group of lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma, colon carcinoma and breast carcinoma.
  • a tumor of the blood and immune system preferably for the treatment of a tumor selected from the group of acute myelotic leukemia, chronic myelotic leukemia, acute lymphatic leukemia and / or chronic lymphatic leukemia.
  • the invention furthermore relates to the use of the compounds of the formula I for the treatment of a disease in which angiogenesis is involved.
  • the disease is preferably an eye disease.
  • the invention further relates to the use for the treatment of retinal vascularization, diabetic retinopathy, age-related macular degeneration and / or inflammatory diseases.
  • the inflammatory disease is preferably selected from the group rheumatoid arthritis, psoriasis, contact dermatitis and late-type hypersensitivity reaction.
  • the invention furthermore relates to the use of the compounds according to the invention for the treatment of bone pathologies, the bone pathology from the group osteosarcoma, osteoarthritis and 5
  • the compounds of formula I are suitable for the manufacture of a medicament for the treatment of diseases caused by Raf kinases
  • Raf kinase being selected from the group consisting of A-Raf, B-Raf and Raf-1.
  • Preferred is the use for the treatment of diseases, preferably from the group of hyperproliferative and not
  • the non-cancerous diseases are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, 0
  • the cancerous diseases are selected from group 5 consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, liver cancer, kidney cancer, colorectal cancer, breast cancer, head cancer, neck cancer, esophageal cancer, gynecological cancer, thyroid cancer, leukemia and leukemia and leukemia 0 ,
  • the compounds of formula I can also be administered together with other well known therapeutic agents which are selected on the basis of their suitability for the condition being treated.
  • other well known therapeutic agents which are selected on the basis of their suitability for the condition being treated.
  • combinations that contain antiresorptive bisphosphonates such as alendronate and risedronate, integrin blockers would be favorable (as defined below) how ⁇ vi3 antagonists nest at which
  • Hormone therapy used conjugated estrogens like Prempro®,
  • SERMs such as raloxifene, droloxifene, CP-336,156 (Pfizer) and lasofoxifene
  • Kathepsin K inhibitors and ATP proton pump inhibitors included.
  • the present compounds are also suitable for combination with known anti-cancer agents.
  • known anti-cancer agents include the following: estrogen receptor modulators, protruding receptor modulators, retinoid receptor modulators, cytotoxics, antiproliferative
  • prenyl protein transferase inhibitors HMG-CoA reductase inhibitors
  • HIV protease inhibitors HIV protease inhibitors
  • reverse transcriptase inhibitors other angiogenesis inhibitors.
  • present compounds are particularly suitable for joint use with radiotherapy.
  • the synergistic effects of inhibiting VEGF in combination with radiotherapy have been described in the specialist field (see WO 00/61186).
  • Estrogen receptor modulators refers to compounds that interfere with or inhibit the binding of estrogen to the receptor, regardless of how this is done.
  • the estrogen receptor modulators include, for example, tamoxifen, raloxifene, idoxifene, LY353381, LY 117081, toremifene, fulvestrant , 4- [7- (2,2-Dimethyl-1-oxopropoxy-4-methyl-2- [4- [2- (1 - piperidinyl) ethoxyphenyl] -2H-1-benzopyran-3-yl] phenyl-2 , 2-dimethylpropanoate, 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone, and SH646, which, however, is not intended to be a limitation.
  • Androgen receptor modulators refers to compounds which interfere with or inhibit the binding of androgens to the receptor, regardless of how this happens, and androgen receptor modulators include, for example, finasteride and other 5 ⁇ -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozo! and abiraterone acetate.
  • Retinoid receptor modulators refers to compounds that interfere with or inhibit the binding of retinoids to the receptor, regardless of how this is done. Such retinoid receptor modulators include, for example, bexarotene, tretinoin, 13-cis retinoic acid,
  • Cytotoxics refers to compounds that are primarily direct
  • Cytotoxic agents include, for example tirapazimine, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, Dibromdulcit, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosylate, trofosfamide, nimustine, Dibrospidium- chloride, Pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-amine dichloro (2-methylpyridine) platinum, benz
  • microtubulin inhibitors include, for example, paclitaxel, vindesine sulfate, S ' ⁇ ' - Dideshydro ⁇ '- deoxy- ⁇ '-norvincaleukoblastin, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR10448761, VinMSin Cryptophycin, 2,3,4,5,6-pentafluoro-N- (3-fluoro-4-methoxyphenyl) benzenesulfonamide, anhydrovinblastine, N, N- dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proIin t-butylamide,
  • Topoisomerase inhibitors are, for example, topotecan, hycaptamine,
  • antiproliferative agents include antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231 and 1NX3001, as well as antimetabolites such as enocitabine, Carmofur, Tegafur, pentostatin, doxifluridine, trimetrexate, flitabinarabine, fludararabin, fludarabin, ocfosfat, fosteabin sodium hydrate, raititrexed, paltitrexide,
  • the “antiproliferative agents” also contain monoclonal antibodies against growth factors other than those already mentioned
  • Angiogenesis inhibitors such as trastuzumab and trastuzumab
  • tumor suppressor genes such as p53, mediated via recombinant virus
  • a c The invention further relates to the use of the compounds of the formula I for the manufacture of a medicament for the treatment of diseases, the disease being characterized by disturbed angiogenesis.
  • the disease is preferably cancer.
  • the disturbed angiogenesis preferably results from an impaired VEGFR-1, VEGFR-2 and / or VEGFR-3 activity. It is therefore particularly preferred to use the compounds according to the invention for the production of a medicament for inhibiting VEGFR-2 activity.
  • VEGF receptor kinase activity is determined by incorporating radioactively labeled phosphate in 4: 1 polyglutamic acid / tyrosine substrate (pEY).
  • pEY polyglutamic acid / tyrosine substrate
  • the phosphorylated pEY product is held on a filter membrane and the incorporation of the radioactively labeled phosphate is quantified by scintillation counting.
  • VEGF receptor kinase The intracellular tyrosine kinase domains of human KDR (Terman, BI et al. Oncogene (1991) Vol. 6, pp. 1677-1683.) And Flt-1 (Shibuya, M. et al. Oncogene (1990) 5, pp. 519-524) were cloned as glutathione-S-transferase (GST) gene fusion proteins. This was done by cloning the cytoplasmic domain of the KDR kinase as a read-frame fusion at the carboxy terminus of the GST gene.
  • GST glutathione-S-transferase
  • the soluble recombinant GST-kinase domain fusion proteins were expressed in Spodoptera frugiperda (Sf21) insect cells (Invitrogen) using a baculovirus expression vector (pAcG2T, Pharmingen). lysis buffer
  • Tris pH 7.4 50 mM Tris pH 7.4, 0.5 M NaCI, 5 mM DTT, 1 mM EDTA, 0.05% Triton X-100, 10% glycerol, 10 mg / ml each of leupeptin, pepstatin and aprotinin and 1 mM phenylmethylsulfonyl fluoride.
  • dialysis buffer 50mM Tris pH 7.4, 0.5M NaCI, 5mM DTT, 1mM EDTA, 0.05% Triton X-
  • reaction buffer 5 200 mM Tris, pH 7.4, 1.0 M NaCl, 50 mM MnCl 2 , 10 mM DTT and 5 mg / ml
  • Bovine serum albumin BSA] (Sigma).
  • Stop Solution Ate 30% trichloroacetic acid, 0.2 M sodium pyrophosphate (both from Fisher).
  • Millipore #MAFC NOB GF / C 96-well glass fiber plate.
  • the Sf21 cells were with the recombinant virus in an m.o.i.
  • VEGF receptors that mediate mitogenic responses to the growth factor is largely restricted to vascular endothelial cells.
  • Cultivated human umbilical vein endothelial cells proliferate in response to treatment with VEGF and 0 can be used as an assay system for quantifying the effects of KDR kinase inhibitors on VEGF stimulation.
  • single cell layers of HUVECs are treated with the constituent or the test compound at rest 2 hours before the addition of VEGF or 5 "basic fibroblast growth factor" (bFGF).
  • the mitogenic response to VEGF or bFGF is measured by measuring the incorporation of [ 3 H] thymidine determined in the cell DNA. 0 materials
  • Frozen HUVECs as primary culture isolates are obtained from Clonetics Corp. The cells are obtained in the endothelial growth medium (EGM; Clonetics) and used in the 3rd to 7th passages for the mitogenicity assays. culture plates
  • NUNCLON 96-well polystyrene tissue culture plates (NUNC # 167008).
  • Dulbecco modified Eagle medium with 1 g / ml glucose (DMEM 5 with low glucose content; Mediatech) plus 10% (v / v) fetal
  • DMSO Dimethyl sulfoxide
  • Bovine serum albumin (Boehringer-Mannheim). 5 cell lysis solution
  • HUVEC single cell layers kept in EGM are harvested by trypsin treatment and inoculated in a density of 4000 cells per 100 ⁇ ⁇ assay medium per well in 96-well plates. The growth of the cells is stopped for 24 hours at 37 ° C. in a humid atmosphere containing 5% CO 2 .
  • the growth stop medium is replaced with 100 ⁇ ⁇ assay medium, which is either the constituent (0.25% [v / v] DMSO) or the desired one Contains final concentration of the test compound. All determinations are carried out in triplicate. The cells then become 2
  • the compounds of the formula I are VEGF inhibitors and are therefore suitable for inhibiting angiogenesis, such as in the treatment of eye diseases, for example diabetic retinopathy, and for the treatment of carcinomas, for example solid tumors.
  • the present compounds inhibit VEGF-stimulated mitogenesis of cultured human vascular endothelial cells with HK50 values of 0.01-5.0 ⁇ M.
  • T / E-2 tests can, for example, be carried out analogously to the methods specified in WO 02/44156.
  • the assay determines the inhibitory activity of the substances to be tested in the phosphorylation of the substrate poly (Glu, Tyr) by Tie-2-kinase in the presence of radioactive 33 P-ATP.
  • the phosphorylated substrate binds to the surface of a "flashplate" microtiter plate during the incubation period. After removing the reaction mixture, it is washed several times and then the radioactivity is measured on the surface of the microtiter plate. An inhibitory effect of the substances to be measured results in a lower radioactivity compared to an undisturbed enzymatic reaction.
  • Example 2 Analogously to Example 1, the following compounds are obtained as trifluoroacetates: A / - [4- (4-Amino-5-oxo-5 - / - pyrido [2,3-c (] pyrimidin-8-yl) phenyl] -3- trifluoromethyl-benzenesulfonamide, EI-MS 462;
  • Example A Injection glasses
  • a solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2 N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized and sterile sealed under sterile conditions , Each injection jar contains 5 mg of active ingredient.
  • a mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.
  • a solution of 1 g of an active ingredient is prepared of the formula I, 9.38 g of NaH 2 P0 4 • 2 H 2 0, 28.48 g Na 2 HP0 4 • 12 H 2 0 and 0.1 g of benzalkonium chloride in 940 ml of double distilled water. It is adjusted to pH 6.8, made up to 1 l and sterilized by irradiation. This solution can be used in the form of eye drops.
  • Example D ointment
  • Example E tablets
  • a mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1, 2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of active ingredient.
  • Example F coated tablets
  • Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.
  • Example G capsules
  • each capsule contains 20 mg of the active ingredient.
  • a solution of 1 kg of active ingredient of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each ampoule contains 10 mg of active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (I), dans laquelle R<6>, R<7>, R<8>, R<9> et X ont les significations mentionnées dans la revendication 1. Lesdits composés sont des inhibiteurs des tyrosine kinases, notamment TIE-2 et des Raf kinases et peuvent s'utiliser entre autres pour traiter des tumeurs.
EP05716154A 2004-04-15 2005-03-17 Sulfonamides Withdrawn EP1737858A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004018198A DE102004018198A1 (de) 2004-04-15 2004-04-15 Sulfonamide
PCT/EP2005/002849 WO2005105797A1 (fr) 2004-04-15 2005-03-17 Sulfonamides

Publications (1)

Publication Number Publication Date
EP1737858A1 true EP1737858A1 (fr) 2007-01-03

Family

ID=34961420

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05716154A Withdrawn EP1737858A1 (fr) 2004-04-15 2005-03-17 Sulfonamides

Country Status (8)

Country Link
US (1) US7528139B2 (fr)
EP (1) EP1737858A1 (fr)
JP (1) JP4891227B2 (fr)
AR (1) AR052302A1 (fr)
AU (1) AU2005238135B2 (fr)
CA (1) CA2563558A1 (fr)
DE (1) DE102004018198A1 (fr)
WO (1) WO2005105797A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2783B1 (en) 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2009158432A2 (fr) 2008-06-27 2009-12-30 Amgen Inc. Inhibition de l’ang-2 pour traiter la sclérose en plaques
BR112012008271A2 (pt) * 2009-10-08 2015-09-22 Glaxosmithkline Llc combinação
PE20121093A1 (es) * 2009-10-16 2012-09-04 Glaxosmithkline Llc Combinacion farmaceutica que comprende un inhibidor de mek y un inhibidor de b-raf
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
CN112063028A (zh) * 2020-08-27 2020-12-11 上海春宜药品包装材料有限公司 生物可降解树脂包装膜及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
WO2002090360A1 (fr) * 2001-05-10 2002-11-14 Smithkline Beecham Corporation Composes utiles comme inhibiteurs de kinases pour le traitement de maladies hyperproliferatives
ATE374201T1 (de) 2002-08-06 2007-10-15 Hoffmann La Roche 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005105797A1 *

Also Published As

Publication number Publication date
US20070244135A1 (en) 2007-10-18
AR052302A1 (es) 2007-03-14
CA2563558A1 (fr) 2005-11-10
AU2005238135B2 (en) 2011-03-10
WO2005105797A1 (fr) 2005-11-10
JP4891227B2 (ja) 2012-03-07
AU2005238135A1 (en) 2005-11-10
DE102004018198A1 (de) 2005-11-03
JP2007532590A (ja) 2007-11-15
US7528139B2 (en) 2009-05-05

Similar Documents

Publication Publication Date Title
EP1866302B1 (fr) Derive de pyrazole
EP1799679B1 (fr) Derives de la n,n&#39;-diphenyluree utilisables comme inhibiteurs de kinases
EP1727820B1 (fr) Derives d&#39;amine ayant une activite en tant qu&#39;inhibiteurs de la tyrosine kinase
EP1809628B1 (fr) Dérivés de phénylurée en tant qu&#39;inhibiteurs de tyrosinkinase pour le traitement des maladies de cancer
EP1912998B1 (fr) Derives de pyrazole presentant une activite tyrosine kinase
EP1809630B1 (fr) Derives de 4-amino-5-oxo-8-phenyl-5h-pyrido[2,3-d]-pyrimidine utilises en tant qu&#39;inhibiteurs des tyrosines kinases et des kinases raf pour traiter des tumeurs
EP1682548B1 (fr) Pyridopyrimidinones pour le traitement des maladies de cancer
WO2006094600A1 (fr) Derives de tetrahydro-pyrrolo-quinoleine substitues servant de modulateurs de kinase, plus specialement de tyrosine kinases et de raf-kinases
EP1664039B1 (fr) Derives de 1,3-benzoxazolyle servant d&#39;inhibiteurs de kinase
WO2006108482A1 (fr) Dérivés de purine en tant qu&#39;inhibiteurs de l&#39;activité de tyrosine kinase réceptrice
EP1809629B1 (fr) Dérivés de N,N&#39;-diphenylurée utiles pour le traitement de tumeurs, de maladies oculaires, d&#39;inflammation et de maladies immunitaires
EP1656377A1 (fr) Derives d&#39;aminobenzimidazole
EP1663988A1 (fr) Derives de benzyl-benzimidazolyle
WO2005105797A1 (fr) Sulfonamides
WO2005097755A2 (fr) Derives d&#39;imidazol
WO2005085220A1 (fr) Utilisation de derives de thiadiazole-uree

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060817

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090824

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20100417